Armata Pharmaceuticals, Inc. Logo

Armata Pharmaceuticals, Inc.

Develops bacteriophage therapeutics for antibiotic-resistant bacterial infections.

ARMP | US

Overview

Corporate Details

ISIN(s):
US04216R1023
LEI:
Country:
United States of America
Address:
5005 MCCONNELL AVE, 90066 LOS ANGELES

Description

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-01 18:17
FORM 8-K
English ZIP 271.6 KB
2025-12-01 18:15
424B5
English ZIP 243.9 KB
2025-11-12 17:16
10-Q
English ZIP 1.5 MB
2025-11-12 17:10
8-K
English ZIP 111.9 KB
2025-10-22 13:15
FORM 8-K
English ZIP 5.5 MB
2025-09-10 20:15
FORM 8-K
English ZIP 17.4 MB
2025-08-25 02:15 English ZIP 5.3 KB
2025-08-20 18:06 English ZIP 30.1 KB
2025-08-15 16:36 English ZIP 57.9 KB
2025-08-13 19:16
FORM S-8
English ZIP 84.7 KB
2025-08-13 19:15
FORM S-3
English ZIP 340.2 KB
2025-08-12 23:38 English ZIP 10.6 KB
2025-08-12 18:36
10-Q
English ZIP 1.5 MB
2025-08-12 18:16
8-K
English ZIP 401.2 KB
2025-07-14 18:05
OWNERSHIP DOCUMENT
English ZIP 7.1 KB

Automate Your Workflow. Get a real-time feed of all Armata Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Armata Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Armata Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ATAI Life Sciences N.V. Logo
Develops psychedelic-inspired therapies for mental health disorders.
United States of America
ATAI
Atea Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing oral antiviral therapies for serious viral diseases.
United States of America
AVIR
Athira Pharma, Inc. Logo
Biopharma firm developing small molecule therapeutics for neurodegenerative diseases.
United States of America
ATHA
ATOSSA THERAPEUTICS, INC. Logo
Clinical-stage biopharmaceutical company developing oncology medicines for breast cancer.
United States of America
ATOS
aTYR PHARMA INC Logo
Develops medicines based on tRNA synthetase biology for fibrosis and inflammation.
United States of America
ATYR
Aura Biosciences, Inc. Logo
Develops Virus-Like Drug Conjugates as targeted therapies for solid tumors.
United States of America
AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharmaceutical company developing therapies for severe autoimmune diseases.
United States of America
AUPH
AURORA CANNABIS INC Logo
Global producer and distributor of cannabis for medical and recreational markets.
United States of America
ACB
Autolus Therapeutics plc Logo
Biopharmaceutical company developing programmed T cell therapies for cancer and autoimmune diseases.
United States of America
AUTL
AVACTA GROUP PLC Logo
Clinical-stage biotech developing targeted oncology drugs with a proprietary platform.
United Kingdom
AVCT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.